Dal-Bianco Assunta, Oh Jiwon, Sati Pascal, Absinta Martina
Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna 1090, Austria.
Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
Ther Adv Neurol Disord. 2024 Dec 19;17:17562864241306684. doi: 10.1177/17562864241306684. eCollection 2024.
In multiple sclerosis (MS), increasing disability is considered to occur due to persistent, chronic inflammation trapped within the central nervous system (CNS). This condition, known as smoldering neuroinflammation, is present across the clinical spectrum of MS and is currently understood to be relatively resistant to treatment with existing disease-modifying therapies. Chronic active white matter lesions represent a key component of smoldering neuroinflammation. Initially characterized in autopsy specimens, multiple approaches to visualize chronic active lesions (CALs) in vivo using advanced neuroimaging techniques and postprocessing methods are rapidly emerging. Among these in vivo imaging correlates of CALs, paramagnetic rim lesions (PRLs) are defined by the presence of a perilesional rim formed by iron-laden microglia and macrophages, whereas slowly expanding lesions are identified based on linear, concentric lesion expansion over time. In recent years, several longitudinal studies have linked the occurrence of in vivo detected CALs to a more aggressive disease course. PRLs are highly specific to MS and therefore have recently been incorporated into the MS diagnostic criteria. They also have prognostic potential as biomarkers to identify patients at risk of early and severe disease progression. These developments could significantly affect MS care and the evaluation of new treatments. This review describes the latest knowledge on CAL biology and imaging and the relevance of CALs to the natural history of MS. In addition, we outline considerations for current and future in vivo biomarkers of CALs, emphasizing the need for validation, standardization, and automation in their assessment.
在多发性硬化症(MS)中,残疾程度的增加被认为是由于中枢神经系统(CNS)内持续存在的慢性炎症所致。这种情况被称为隐匿性神经炎症,在MS的整个临床谱系中都存在,目前已知其对现有疾病修正疗法相对耐药。慢性活动性白质病变是隐匿性神经炎症的关键组成部分。最初在尸检标本中得以表征,如今,利用先进神经成像技术和后处理方法在体内可视化慢性活动性病变(CALs)的多种方法正在迅速涌现。在这些CALs的体内成像关联因素中,顺磁性边缘病变(PRLs)由富含铁的小胶质细胞和巨噬细胞形成的病变周围边缘所定义,而缓慢扩展病变则是基于病变随时间呈线性、同心性扩展来识别。近年来,多项纵向研究已将体内检测到的CALs的出现与更具侵袭性的疾病进程联系起来。PRLs对MS具有高度特异性,因此最近已被纳入MS诊断标准。它们还具有作为生物标志物的预后潜力,可用于识别有早期和严重疾病进展风险的患者。这些进展可能会显著影响MS的治疗及新疗法的评估。本综述描述了关于CAL生物学和成像的最新知识以及CALs与MS自然史的相关性。此外,我们概述了当前及未来CALs体内生物标志物的相关考量因素,强调在其评估中进行验证、标准化和自动化的必要性。